1 – 10 of 51
      - show: 10
- |
- sort: year (new to old)
        Close
        
            
    
    Embed this list
<iframe src=""
              width=""
              height=""
              allowtransparency="true"
              frameborder="0">
            </iframe>
        - 2019
- 
                        Mark
        Dread and Risk Elimination Premium for the Value of a Statistical Life
    
    - Contribution to journal › Article
 
- 2018
- 
                        Mark
        Measuring the end-of-life premium in cancer using individual ex ante willingness to pay
    
    - Contribution to journal › Article
 
- 
                        Mark
        Intraductal papillary mucinous neoplasms of the pancreas – a cost-effectiveness analysis of management strategies for the branch-duct subtype
    
    - Contribution to journal › Article
 
- 2016
- 
                        Mark
        Social/economic costs and health-related quality of life of mucopolysaccharidosis patients and their caregivers in Europe
    
    - Contribution to journal › Article
 
- 
                        Mark
        Social/economic costs and health-related quality of life in patients with cystic fibrosis in Europe
    
    - Contribution to journal › Article
 
- 2015
- 
                        Mark
        Real-world cost-effectiveness in chronic myeloid leukemia: the price of success during four decades of development from non-targeted treatment to imatinib
    
    - Contribution to journal › Article
 
- 
                        Mark
        Register-Based Evaluation of Relative Effectiveness of New Therapies: Biologics Versus Conventional Agents in Treatment of Psoriasis in Sweden.
    
    - Contribution to journal › Article
 
- 
                        Mark
        The End of the International Reference Pricing System?
    (2015) In Applied Health Economics and Health Policy- Contribution to journal › Article
 
- 
                        Mark
        Resource Use in Patients with Psoriasis After the Introduction of Biologics in Sweden
    
    - Contribution to journal › Article
 
- 2014
- 
                        Mark
        Willingness to pay for a new drug delivery in Parkinson patients.
    
    - Contribution to journal › Article
 
